Breast cancer patients taking Abraxane in a Phase III trial responded almost twice as well as they did when taking a marketed product - providing American BioScience Inc. and American Pharmaceutical Partners Inc. (APP) the data they needed to file a new drug application. (BioWorld Today)

Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today)